CorMedix Inc. — Director's Dealing 2012

Sep 24, 2012

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2012-05-14

Reporting Person: MILBY RANDY (Chief Operating Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.29	2022-05-14	Common Stock, $0.001 par value per share (50000)		Indirect

Footnotes

F1: These options vest 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate.

F2: The reporting person through his ownership interest in MW Bridges LLC (an entity through which he has voting and investment control) granted options which vest 100% upon receipt of CE Mark approval for the Company's Neutrolin product candidate.